The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression
| العنوان: | The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression |
|---|---|
| المؤلفون: | Meijuan Xiao, Siyan Chen, Jincai He, Liang Feng, Qiongzhang Wang, Xiaoqian Luan |
| المصدر: | International Journal of Geriatric Psychiatry. 36:182-189 |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Sleep Wake Disorders, medicine.medical_specialty, Bright light therapy, Depression, business.industry, Therapeutic effect, Citalopram, Phototherapy, Escitalopram Oxalate, Pittsburgh Sleep Quality Index, Psychiatry and Mental health, Regimen, Treatment Outcome, Sleep Initiation and Maintenance Disorders, Internal medicine, mental disorders, medicine, Insomnia, Humans, Geriatrics and Gerontology, medicine.symptom, business, Adverse effect, Depression (differential diagnoses) |
| الوصف: | INTRODUCTION Bright light therapy (BLT) is known to treat depression and sleep disorders in clinical practice, but its efficacy on poststroke depression (PSD) has not been studied. OBJECTIVE To investigate the therapeutic effects and safety of BLT combined with escitalopram oxalate (ESC) on insomnia in patients with PSD. METHODS Ischemic stroke patients with depressive symptoms and a score of ≥8 on the Hamilton Depression Scale (HAMD-17) while meeting DSM-IV criteria were diagnosed as having PSD. A total of 112 PSD patients with symptoms of insomnia were randomly assigned to polytherapy (BLT plus ESC) and monotherapy (ESC only) groups. Each regimen continued for 6 weeks. The primary outcomes were a change in scores on the Pittsburgh Sleep Quality Index (PSQI) and a remission rate (PSQI ≤7 at the endpoint). The secondary outcomes included changes in the HAMD-17 and Barthel Index (BI) scores. Adverse effects were assessed by the Adverse Events Scale. RESULTS The endpoint assessment included 106 patients (monotherapy, 54; polytherapy, 52). The mean changes in the PSQI scores for the monotherapy and polytherapy groups were 4.85 (1.47) and 5.87 (1.72) (P = 0.001), respectively. Compared to monotherapy, polytherapy improved PSQI remission rate (71.4% vs 50.0%; χ2 = 5.390; P = 0.020), and HAMD-17 score (6.70 [2.12] vs 4.75 [1.98]; P |
| تدمد: | 1099-1166 0885-6230 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd701262051ca21e4bde78b0f7efc8eb https://doi.org/10.1002/gps.5412 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....bd701262051ca21e4bde78b0f7efc8eb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10991166 08856230 |
|---|